Cargando…

Aflibercept monotherapy versus aflibercept with targeted retinal laser to peripheral retinal ischemia for diabetic macular oedema (LADAMO)

OBJECTIVE: We tested the hypothesis that targeted retinal laser photocoagulation (TPRP) to peripheral retinal ischaemia reduces the overall burden of aflibercept injections when treating diabetic macular oedema (DMO) over a 24-month period. METHODS: Prospective, double-masked, multicentre, randomise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cornish, E. E., Wickremasinghe, S., Mehta, H., Lim, L., Sandhu, S. S., Nguyen, V., Gillies, M. C., Fraser-Bell, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630305/ https://www.ncbi.nlm.nih.gov/pubmed/37069239 http://dx.doi.org/10.1038/s41433-023-02525-9

Ejemplares similares

12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry
por: Niedzwiecki, Mateusz, et al.
Publicado: (2021)

A treat and extend protocol with Aflibercept for cystoid macular oedema secondary to central retinal vein occlusion – an 18-month prospective cohort study
por: O’Day, Roderick, et al.
Publicado: (2020)

Macular Oedema in Idiopathic Macular Telangiectasia Type 1 Responsive to Aflibercept but Not Bevacizumab
por: Shibeeb, O'Sam, et al.
Publicado: (2014)

Retinal arteriolar oxygen saturation predicts the need for intravitreal aflibercept in patients with diabetic macular oedema
por: Blindbæk, Søren Leer, et al.
Publicado: (2020)

Prospective exploratory study to assess the safety and efficacy of aflibercept in cystoid macular oedema associated with retinitis pigmentosa
por: Strong, Stacey A, et al.
Publicado: (2020)

Navigated laser and aflibercept versus aflibercept monotherapy in treatment‐naïve branch retinal vein occlusion: A 12‐month randomized trial
por: Frederiksen, Katrine Hartmund, et al.
Publicado: (2022)

Effects of Switching to Aflibercept in Treatment Resistant Macular Edema Secondary to Retinal Vein Occlusion
por: Spooner, Kimberly, et al.
Publicado: (2020)

Comment on: Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion
por: Elkazza, Sumeia A, et al.
Publicado: (2020)

Aflibercept versus ranibizumab for treating persistent diabetic macular oedema
por: ROA Vandekerckhove, Kristof
Publicado: (2015)

Randomized clinical trial comparing intravitreal aflibercept combined with subthreshold laser to intravitreal aflibercept monotherapy for diabetic macular edema
por: Tatsumi, Tomoaki, et al.
Publicado: (2022)

Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Konidaris, Vasileios E., et al.
Publicado: (2018)

Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept
por: de Oliveira Dias, João Rafael, et al.
Publicado: (2016)

Intravitreal aflibercept for treatment of macular oedema associated with immune recovery uveitis
por: Rothova, Aniki, et al.
Publicado: (2020)

Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
por: Paulose, Remya, et al.
Publicado: (2016)

Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Management of macular edema due to central retinal vein occlusion – The role of aflibercept
por: Rhoades, William, et al.
Publicado: (2017)

Role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept
por: Mansour, Ahmad M, et al.
Publicado: (2019)

Ziv-aflibercept in macular disease
por: Mansour, Ahmad M, et al.
Publicado: (2015)

Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Efficacy of a Modified Treat-and-Extend Aflibercept Regimen for Macular Oedema in Eyes with Central Retinal Vein Occlusion: 2-Year Prospective Study
por: Arai, Yusuke, et al.
Publicado: (2023)

Intravitreal sirolimus with adjunct aflibercept versus aflibercept monotherapy for persistent, exudative age-related macular degeneration: a pilot study
por: Rowe, Lucas W., et al.
Publicado: (2023)

Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion
por: Chhablani, Jay
Publicado: (2015)

Aflibercept in macular edema secondary to retinal vein occlusion: A real life study
por: Ozkaya, Abdullah, et al.
Publicado: (2017)

One-year outcomes of ziv-aflibercept for macular edema in central retinal vein occlusion
por: Eldeeb, Mohab, et al.
Publicado: (2017)

Effects of Intravitreal Aflibercept on Retinal Function and Improvement of Macular Edema Associated With Diabetic Retinopathy
por: Ichio, Atsushi, et al.
Publicado: (2020)

New individualized aflibercept treatment protocol for branch retinal vein occlusion with macular edema
por: Noma, Hidetaka, et al.
Publicado: (2023)

Aflibercept for the Treatment of Macular Edema Secondary to Idiopathic Retinal Vasculitis, Aneurysms, and Neuroretinitis Syndrome
por: López Fontanet, José, et al.
Publicado: (2023)

Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab (Lucentis): A Case Report
por: Strong, Stacey A., et al.
Publicado: (2016)

Outcomes of Combination Therapy using Aflibercept and Dexamethasone Intravitreal Implant versus Dexamethasone Monotherapy for Macular Edema Secondary to Retinal Vein Occlusion
por: Harb, Walid, et al.
Publicado: (2021)

Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: An Irish Retrospective Study
por: McCloskey, Clare F., et al.
Publicado: (2018)

Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema
por: Kim, Yu Cheol, et al.
Publicado: (2020)

THREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: Data from the Fight Retinal Blindness! Registry
por: Gabrielle, Pierre-Henry, et al.
Publicado: (2022)

Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy
por: Miyakubo, Tomoko, et al.
Publicado: (2023)

Retinal vasoproliferative tumor regression after intravitreal aflibercept
por: Chu, Ting-Wen, et al.
Publicado: (2022)

Comparison of the Efficacy of Intravitreal Aflibercept and Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
por: Wang, Jia-Kang, et al.
Publicado: (2016)

Role of aflibercept for macular edema following branch retinal vein occlusion: comparison of clinical trials
por: Oellers, Patrick, et al.
Publicado: (2016)

Comment on: Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion
por: Sen, Alok, et al.
Publicado: (2015)

Intravitreal Aflibercept as a Rescue Therapy for Retinal Neovascularization and Macular Edema due to Eales Disease
por: Hsia, Ning-Yi, et al.
Publicado: (2021)

Translating evidence into practice: recommendations by a UK expert panel on the use of aflibercept in diabetic macular oedema
por: Pearce, Ian, et al.
Publicado: (2019)

Retinal pigment epithelium tear after intravitreal aflibercept injection
por: Saito, Masaaki, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_n4k7adlukpoocmme7riiq1278a